Prosensa Holding NV Company Profile (NYSE:RNA)

Analyst Ratings

Consensus Ratings for Prosensa Holding NV (NYSE:RNA) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Prosensa Holding NV (NYSE:RNA)
Show:
DateFirmActionRatingPrice TargetActions
11/25/2014Credit Suisse Group AGBoost Price TargetNeutral$9.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/25/2014Roth CapitalDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/25/2014KBC SecuritiesDowngradeBuy -> Hold$17.00 -> $19.80View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/20/2014JPMorgan Chase & Co.UpgradeUnderweight -> Overweight$4.40 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/31/2014Oppenheimer Holdings Inc.Initiated CoverageOutperform$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Prosensa Holding NV (NYSE:RNA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
11/17/2014Q314($0.25)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214($0.36)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/20/2014Q114$0.01$0.26ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2014($0.14)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Prosensa Holding NV (NYSE:RNA)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Prosensa Holding NV (NYSE:RNA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Prosensa Holding NV (NYSE:RNA)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Prosensa Holding NV (NYSE:RNA)
DateHeadline
04/29/15 03:32 PMBioMarin Upgraded to Strong Buy, Is It in Your Portfolio? - Analyst Blog -
03/31/15 06:53 AMHow bubbles are blown: Biotech edition -
03/27/15 05:40 PMBioMarin Pharma Hits All-Time High -
03/03/15 09:09 AMBioMarin Pharmaceutical Inc. (BMRN) and Other Top New Picks of Healthcare-Focused Visium Asset Management -
02/19/15 03:59 PMWhy Muscular Dystrophy Is Biotech's Favorite Orphan -
02/10/15 03:17 PMProsensa Announces Voluntary Delisting and Advance Liquidation Distribution - [at noodls] - LEIDEN, The Netherlands, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company"), the biopharmaceutical company focusing on RNA-modulating ...
01/31/15 12:53 AMProsensa Announces Intent to Voluntarily Delist From NASDAQ - [at noodls] - LEIDEN, The Netherlands, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company"), the biopharmaceutical company focusing on RNA-modulating ...
01/30/15 07:09 AMBioMarin Announces Final Results of Tender Offer for Prosensa's Shares and Completion of Subsequent Offering Period - [at noodls] - January 30, 2015 SAN RAFAEL, Calif., Jan. 30, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the final results of, and the completion of the subsequent offering period ...
01/22/15 05:00 PMBioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog -
01/21/15 05:25 AMState Of The Union Lights Up Biotech -
01/14/15 04:10 PMBioMarin Gains on Vimizim 2014 View, Batten Disease Data - Analyst Blog -
01/13/15 09:43 AMProsensa Announces Shareholder Approval of Certain Matters Relating to the BioMarin Tender Offer - [at noodls] - Leiden, The Netherlands, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, ...
11/24/14 03:49 PMUS STOCKS-S&P 500 ticks up to record on central bank bets -
11/24/14 02:19 PMUS STOCKS-Wall St up on central bank bets, deals support -
11/24/14 11:34 AMUS STOCKS-Wall St hits new records, but telecom weighs on Dow -
11/24/14 10:18 AMUS STOCKS-Wall St hits new records, boosted by cyclicals -
11/24/14 09:57 AMBuying Glaxo's Biotech Stock Throwbacks Proves Profitable -
11/24/14 09:04 AMUS STOCKS-Wall St surges to new records, boosted by cyclicals -
11/24/14 08:15 AMBig News for Ebola Stocks -
11/24/14 07:52 AMUS STOCKS-Futures point to higher open on merger activity -
11/24/14 07:14 AMUS STOCKS-Futures rise, boosted by merger activity -
11/24/14 06:35 AMBioMarin Pharma offers about $680M for Prosensa -
11/24/14 05:24 AMBioMarin to buy Prosensa in $840 mln deal -

Social

About Prosensa Holding NV

Prosensa Holding NV logoProsensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company's primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. The Company's clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company's platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: RNA
  • CUSIP:
Key Metrics:
  • Previous Close: $19.00
  • 50 Day Moving Average: $0
  • 200 Day Moving Average: $17
  • P/E Ratio: N/A
  • P/E Growth: 0
  • Market Cap: $N/A
  • Current Year EPS Consensus Estimate: $-1 EPS
  • Next Year EPS Consensus Estimate: $-1 EPS
Additional Links:
Prosensa Holding NV (NYSE:RNA) Chart for Sunday, July, 24, 2016